Generated by AI
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology. The company develops cancer medicines using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which is designed to match drug mechanisms with the biological drivers of each tumor and identify patients most likely to respond. Its current work centers on targeted therapies and companion diagnostics for solid tumors, with programs spanning DNA damage response and cell-cycle regulation pathways. Acrivon Therapeutics also develops its OncoSignature diagnostic approach to support patient selection in clinical development. Headquartered in Watertown, Massachusetts, Acrivon Therapeutics plays a specialized role in the biopharmaceutical market by combining drug discovery, biomarker development, and clinical research to advance more selective oncology treatments.
Website480 Arsenal Way
Watertown, MA, 02472
United States
The latest articles about ACRV.
Asset acquisition establishes immunology and inflammation (I&I) as a strategic pillar alongside oncology, extending the company into autoimmune disease As part of Acrivon’s due diligence, extensive AP3 profiling against approved JAK inhibitors and dupilumab revealed ACR-525 as a highly-selective, potentially best-in-class JAK1 inhibitor Eosinophilic esophagitis (EoE) targeted as first potential indication using a Phase 2-ready formulation of ACR-525 designed for patients with difficulty swallowi
Summary of Feb 27's posts. Generated by AI.
Summary of Jan 16's posts. Generated by AI.
No summary yet.
Summary of Jan 8's posts. Generated by AI.
Investors talking about ACRV also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.